Does route of administration affect the outcome of TNF antagonist therapy?

被引:0
|
作者
Sergio Schwartzman
G James Morgan
机构
[1] Hospital for Special Surgery,
[2] Dartmouth-Hitchcock Medical Center,undefined
关键词
adherence; efficacy; intravenous; rheumatoid arthritis; subcutaneous; tumor necrosis factor;
D O I
暂无
中图分类号
学科分类号
摘要
The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy.
引用
收藏
相关论文
共 50 条
  • [1] Does route of administration affect the outcome of TNF antagonist therapy?
    Schwartzman, S
    Morgan, GJ
    ARTHRITIS RESEARCH & THERAPY, 2004, 6 (Suppl 2) : S19 - S23
  • [2] Does Route of Hysterectomy Affect Outcome in Obese and Nonobese Women?
    Brezina, Paul R.
    Beste, Todd M.
    Nelson, Keith H.
    JSLS-JOURNAL OF THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS, 2009, 13 (03) : 358 - 363
  • [3] Smoking does not affect outcome of BCG therapy
    Annette Fenner
    Nature Reviews Urology, 2011, 8 (2) : 64 - 64
  • [4] Hormone replacement therapy - does route of administration matter?
    Tkaczuk-Wlach, Joanna
    Sobstyl, Malgorzata
    Wlach, Rafal
    Jakiel, Grzegorz
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2013, 12 (06): : 504 - 508
  • [5] Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles
    Zikopoulos, K
    Kolibianakis, EM
    Camus, M
    Tournaye, H
    Van den Abbeel, E
    Joris, H
    Van Steirteghem, A
    Devroey, P
    FERTILITY AND STERILITY, 2004, 81 (02) : 473 - 475
  • [6] Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist
    Mustafa Bahceci
    Ulun Ulug
    Journal of Assisted Reproduction and Genetics, 2008, 25 : 499 - 502
  • [7] Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist
    Bahceci, Mustafa
    Ulug, Ulun
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2008, 25 (9-10) : 499 - 502
  • [8] DOES SEVERITY OF OAB AFFECT THE OUTCOME OF CONSERVATIVE THERAPY?
    Obloza, A.
    Teo, R. C.
    Mayne, C.
    Lane, K.
    Tincello, D. G.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2017, 28 : S223 - S223
  • [9] Does route of administration affect erythropoietin concentration in the blood and brain of neonatal rats?
    Statler, P
    McPherson, R
    Juul, S
    JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S111 - S111
  • [10] Route to Lung Cancer Diagnosis in the UK: How Does This Affect Patient Outcome?
    Ng, S. M.
    Pan, J.
    Gareeboo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1990 - S1991